BETA
Your AI-Trained Oncology Knowledge Connection!
Naveen Pemmaraju, MD, discusses adverse effects associated with JAK inhibitors in the treatment of myelofibrosis, and the Oncology Brothers recap the entire discussion.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
GLP-1 Agonists Show Therapeutic Benefits in Polycythemia Vera Population
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Reprogramming the Neuroblastoma Tumor Immune Microenvironment to Enhance GPC2 CAR T-cells
CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025
Rusfertide Earns FDA BTD for Erythrocytosis in Polycythemia Vera
Cross-Collaboration is Key for Cellular Therapies Options Across Cancer Types